CeCil: A Randomized, Non-comparative Clinical Trial of the Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma.

Trial Profile

CeCil: A Randomized, Non-comparative Clinical Trial of the Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cilengitide (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms CeCil
  • Most Recent Events

    • 21 Mar 2012 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Trial design reported at the Trials in Progress Poster Session at ASCO 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top